Massmutual Trust Co. FSB ADV Purchases 315 Shares of Eli Lilly and Company (NYSE:LLY)

Massmutual Trust Co. FSB ADV increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 9.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,534 shares of the company’s stock after purchasing an additional 315 shares during the period. Massmutual Trust Co. FSB ADV’s holdings in Eli Lilly and Company were worth $3,200,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in shares of Eli Lilly and Company by 71.3% during the 2nd quarter. GAMMA Investing LLC now owns 11,658 shares of the company’s stock worth $10,555,000 after acquiring an additional 4,853 shares in the last quarter. Transcend Capital Advisors LLC increased its stake in shares of Eli Lilly and Company by 9.8% in the 2nd quarter. Transcend Capital Advisors LLC now owns 16,931 shares of the company’s stock valued at $15,329,000 after purchasing an additional 1,518 shares during the last quarter. Centre Asset Management LLC lifted its position in shares of Eli Lilly and Company by 2.3% during the 2nd quarter. Centre Asset Management LLC now owns 7,723 shares of the company’s stock worth $6,992,000 after buying an additional 172 shares during the last quarter. Neville Rodie & Shaw Inc. grew its holdings in shares of Eli Lilly and Company by 1.4% during the 2nd quarter. Neville Rodie & Shaw Inc. now owns 15,373 shares of the company’s stock valued at $13,919,000 after purchasing an additional 207 shares during the last quarter. Finally, Kathmere Capital Management LLC increased its position in Eli Lilly and Company by 4.8% during the 2nd quarter. Kathmere Capital Management LLC now owns 4,871 shares of the company’s stock worth $4,410,000 after purchasing an additional 224 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Truist Financial restated a “buy” rating and set a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Bank of America reiterated a “buy” rating and issued a $1,000.00 price objective on shares of Eli Lilly and Company in a report on Monday, June 24th. Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $855.00 to $884.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Berenberg Bank upped their price target on Eli Lilly and Company from $850.00 to $1,000.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $860.05.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 2,052 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the sale, the insider now directly owns 98,554,195 shares of the company’s stock, valued at approximately $79,730,343,755. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the transaction, the insider now owns 98,554,195 shares of the company’s stock, valued at approximately $79,730,343,755. The disclosure for this sale can be found here. Insiders have sold a total of 1,214,704 shares of company stock valued at $1,066,841,316 over the last 90 days. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 3.6 %

LLY traded down $29.20 during trading on Monday, hitting $775.26. 4,658,440 shares of the company’s stock were exchanged, compared to its average volume of 3,012,862. Eli Lilly and Company has a fifty-two week low of $450.58 and a fifty-two week high of $966.10. The stock has a market cap of $736.81 billion, a P/E ratio of 114.68, a PEG ratio of 1.81 and a beta of 0.41. The business’s 50 day moving average is $870.80 and its two-hundred day moving average is $790.05. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.67%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.